Article Details

Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) Receives Consensus Rating of "Buy" from ...

Retrieved on: 2021-06-15 13:30:00

Tags for this article:

Click the tags to see associated articles and topics

Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) Receives Consensus Rating of "Buy" from .... View article details on hiswai:

Excerpt

Truist Securities boosted their target price on shares of Dicerna Pharmaceuticals from $35.00 to $45.00 in a research report on Monday, April 19th.

Article found on: www.marketbeat.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up